Global Blood Safety Resources

This is the powerpoint presentation file of Leni von Bonsdorff from Day 3 Session 2 The Way Forward.

This is the powerpoint presentation file of Mariángela Vargas from Day 3 Session 1 Scale-up for domestic processing of plasma: technology options, equipment and oversight.

This is the powerpoint presentation file of Tomoko Hongo-Hirasaki from Day 3 Session 1 Scale-up for domestic processing of plasma: technology options, equipment and oversight.

This is the powerpoint presentation file of Josephine Cheng from Day 3 Session 1 Scale-up for domestic processing of plasma: technology options, equipment and oversight.

This is the powerpoint presentation file of Prity Bengani-Lutz from Day Session 1 Scale-up for domestic processing of plasma: technology options, equipment and oversight.

This is the powerpoint presentation file of Magdy El-Ekiaby from Day 2 Session 1 Options to improve the access to safe plasma protein products in LMIC.

This is the powerpoint presentation file of Salwa Hindawi from Day 2 Session 1 Options to improve the access to safe plasma protein products in LMIC.

This is the powerpoint presentation file of Pierre Tiberghien from Day 2 Session 1 Options to improve the access to safe plasma protein products in LMIC.

This is the powerpoint presentation file of Jeffrey McCullough from Day 2 Session 1 Options to improve the access to safe plasma protein products in LMIC.

This is the powerpoint presentation file of Giuliano Grazzini from Day 2 Session 1 Options to improve the access to safe plasma protein products in LMIC.

This is the powerpoint presentation file of Jan Bult from Day 1 Session 2 Options for fractionation of domestic plasma.

This is the powerpoint presentation file of Vee Armstrong from Day 1 Session 2 Options for fractionation of domestic plasma.

This is the powerpoint presentation file of Françoise Rossi from Day 1 Session 2 Options for fractionation of domestic plasma.

This is the powerpoint presentation file of Johan Prevot from Day 1 Session 1 Unmet Needs for Plasma-derived Medicinal Products in Low- and Middle-income Countries.